A dendritic cell line genetically modified to express CTLA4-Ig as a means to prolong islet allograft survival

Transplantation

Volumn 69, Issue 7, 2000, Pages 1440-1446

  O'Rourke, Robert W ^a   Kang, Sang Mo ^a   Lower, Jennifer A ^a   Feng, Sandy ^b   Ascher, Nancy L ^a   Baekkeskov, Steinunn ^a   Stock, Peter G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; STREPTOZOCIN;

ALLOGRAFT; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DNA MODIFICATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT SURVIVAL; IMMUNE RESPONSE; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

EID: 0034655834     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200004150-00039     Document Type: Article

References (23)

1. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561.
2. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg [see comments]. Science 1992; 257: 789.
3. Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994; 58: 602.
4. Stingl G, Bergstresser PR. Dendritic cells: a major story unfolds. Immunol Today 1995; 16: 330.
5. Rastellini C, Lu L, Ricordi C, Starzl TE, Rao AS, Thomson AW. Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation 1995; 60: 1366.
6. Fu F, Li Y, Qian S, et al. Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+ , CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation 1996; 62: 659.
7. Clare-Salzler MJ, Brooks J, Chai A, Van Herle K, Anderson C. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest 1992; 90: 741.
8. Khoury SJ, Gallon L, Chen W, et al. Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J Exp Med 1995; 182: 357.
9. Lutz MB, Granucci F, Winzler C, et al. Retroviral immortalization of phagocytic and dendritic cell clones as a tool to investigate functional heterogeneity. J Immunol Methods 1994; 174: 269.
10. Bachmann MF, Lutz MB, Layton GT, et al. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol 1996; 26: 2595.
11. Kang SM, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction [see comments]. Nat Med 1997; 3: 738.
12. Altenschmidt U, Ricciardi-Castagnoli P, Modolell M, et al. Bone marrow-derived macrophage lines and immortalized cloned macrophage and dendritic cells support priming of Borrelia burgdorferi-specific T cell responses in vitro and/or in vivo. Immunol Lett 1996; 50: 41.
13. Chahine AA, Yu M, McKernan MM, Stoeckert C, Lau HT. Immunomodulation of pancreatic islet allografts in mice with CTLA4Ig secreting muscle cells. Transplantation 1995; 59: 1313.
14. Campos L, Alfrey EJ, Posselt Am, Odorico JS, Barker CF, Naji A. Prolonged survival of rat orthotopic liver allografts after intrathymic inoculation of donor-strain cells. Transplantation 1993; 55: 866.
15. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801.
16. Bolling SF, Lin H, Wei RQ, Turka LA. Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing. J Heart Lung Transplant 1996; 15: 928.
17. Lee WC, Zhong C, Qian S, et al. Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta. Transplantation 1998; 66: 1810.
18. Buer J, Lanoue A, Franzke A, Garcia C, von Boehmer H, Sarukhan A. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. J Exp Med 1998; 187: 177.
19. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
20. Pearson TC, Alexander DZ, Hendrix R, et al. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model: evidence for hematopoietic chimerism. Transplantation 1996; 61: 997.
21. Ramsdell F, Fowlkes BJ. Maintenance of in vivo tolerance by persistence of antigen. Science 1992; 257: 1130.
22. Winzler C, Rovere P, Rescigno M, et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997; 185: 317.
23. Steptoe RJ, Thomson AW. Dendritic cells and tolerance induction. Clin Exp Immunol 1996; 105: 397.